Clinical spectrum of lysosomal storage disorders in children
DOI:
https://doi.org/10.18203/2349-3291.ijcp20221860Keywords:
Lysosomal storage disorder, Clinical features, Enzyme replacement therapyAbstract
Lysosomal storage diseases (LSDs) are inherited metabolic diseases that are characterized by the accumulation of various toxic metabolites as a result of enzyme deficiencies. LSDs comprises of more than 50 diseases and are classified on a biochemical basis and the type of accumulated substrate. Most of the LSDs are inherited as autosomal recessive disorders with a few exceptions. Gaucher disease is the most common LSD. Clinical presentation of these children usually includes- anaemia, easy bruising, abnormally enlarged liver and/or spleen. We report a case series of 12 children with LSD. Among them 9 (75%) with GD, 3 (25%) with MPS. Based on the symptoms, in reducing order of frequency, children presented with generalised weakness, growth failure, abdominal distension, and developmental delay. 3 children with MPS had coarse facial features with reduced joint movements and hearing impairment. On examination, 5 children (41.6%) weighed less than third percentile, 9 (75%) had short stature, 10 (83%) had moderate to severe visceromegaly, CNS involvement in 2 children seen as hypotonia, occulomotor apraxia. Hematological parameters in all revealed- anaemia/leucopenia/thrombocytopenia- with two or more of the cell lines being affected. Bone marrow biopsy done in 9 (75%) children all of which were abnormal. Most of the children had enzyme activity levels between 0 to less than 15% of the normal reference range of the respective enzyme. ERT was initiated in 9 children (7 GD children and 2 MPS child) and followed up, showed a gradual amelioration in the symptoms by 1 year of regular ERT.
References
Nair V, Belanger EC, Veinot JP. Lysosomal storage disorders affecting the heart: a review. Cardiovasc Pathol. 2019;39:12-24.
Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Cl En. 2015; 29(2):145-57.
Bajaj S, Magar S, Sheth J. Lysosomal storage disorders: an underdiagnosed metabolic disorder. Indian Practition. 2020;73(6):26-32.
Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007;93(4):528-35.
Al-Jasmi FA, Tawfig N, Berniah A, Ali BR, Taleb M, Hertecant JL, et al. Prevalence and novel mutations of lysosomal storage disorders in United Arab Emirates. JIMD Rep. 2012;10:1-9.
Giugliani R, Brusius-Facchin AC, Pasqualim G, Leistner-Segal S, Riegel M, Matte U. Current molecular genetics strategies for the diagnosis of lysosomal storage disorders. Expert Rev Mol Diagn. 2016;16(1):113-23.
Verma PK, Ranganath P, Dalal AB, Phadke SR. Spectrum of lysosomal storage disorders at a medical genetics center in Northern India. Indian Pediatr. 2012;49:799-804.
Poswar FD, Vairo F, Burin M, Michelin-Tirelli K, Brusius-Facchin AC, Kubaski F, et al. Lysosomal diseases: Overview on current diagnosis and treatment. Genet Mol Biol. 2019;42(1):165-77.
Wraith JE. The clinical presentation of lysosomal storage disorders. Acta Neurol Taiwan. 2004;13(3): 101-6.
Beck M. Variable clinical presentation in lysosomal storage disorders. J Inherit Metab Dis. 2001;24(52): 47-51.
Muranjan A. Enzyme replacement therapy for lysosomal storage disorders in India. Mol Cytogen 2014;7(1):I29.
Burin MG, Scholz AP, Gus R, Sanseverino MV, Fritsh A, Magalhaes JA, et al. Investigation of lysosomal storage diseases in non-immune hydrops fetalis. Prenat Diagn. 2004;24:653-7.
Singh A, Prasad R, Mishra OP. Spectrum of lysosomal storage disorders at tertiary centre: Retrospective case-record analysis. J Pediatr Gen. 2020;9(02):87-92.
Magar S, Sangle A, Kale A, Engade M, Vaidya V, et al. The spectrum of lysosomal storage diseases at paediatric genetic clinic in Maharastra, India. Int J Sci Res. 2019;8(9):479-81.
